Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00360763
Status:
UNKNOWN
Last Update Posted:
2006-08-07
First Post:
2006-08-04
Brief Title:
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Sponsor:
Huazhong University of Science and Technology
Organization:
Huazhong University of Science and Technology
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2006-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The autoantibodies against AT1 receptor ATR-AA behaving like an agonist were detected in patients with hypertension ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None